FDA Clears New Methylphenidate Formulation for ADHD

07:39 EDT 20 Jun 2017 | Medscape

Cotempla XR-ODT is a once-daily extended-release orally disintegrating tablet formulation of methylphenidate for patients aged 6 to 17 years with ADHD.
FDA Approvals

Original Article: FDA Clears New Methylphenidate Formulation for ADHD


More From BioPortfolio on "FDA Clears New Methylphenidate Formulation for ADHD"

Quick Search


Relevant Topics

Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...